|IMPORTANT SAFETY INFORMATION (CONT'D)
The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue,
nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation.
Please see full Prescribing Information, including Boxed Warning, for complete information on Qelbree or visit www.QelbreeHCP.com.
REFERENCE: 1. Strattera [package insert]. Indianapolis, IN: Eli Lilly and Company.
Qelbree is a registered trademark of Supernus Pharmaceuticals, Inc. Rethink ADHD Symptom Control is a trademark of Supernus Pharmaceuticals, Inc.
©2022 Supernus Pharmaceuticals, Inc. All rights reserved. QBE.2022-0071 03/22